Nuvalent (NASDAQ:NUVL) Downgraded by Truist Financial to Hold

Nuvalent (NASDAQ:NUVL) was downgraded by analysts at Truist Financial from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

NUVL has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Stifel Nicolaus set a $124.00 price target on shares of Nuvalent in a report on Tuesday. Guggenheim cut Nuvalent from a “buy” rating to a “neutral” rating and cut their target price for the company from $151.00 to $124.00 in a research note on Wednesday. Canaccord Genuity Group cut Nuvalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Finally, UBS Group cut Nuvalent from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $138.00 to $124.00 in a report on Wednesday. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $131.15.

Nuvalent Stock Performance

Shares of NASDAQ:NUVL opened at $123.35 on Tuesday. The stock has a market capitalization of $9.74 billion, a price-to-earnings ratio of -20.35 and a beta of 1.15. Nuvalent has a 52-week low of $71.13 and a 52-week high of $123.62. The stock’s 50-day simple moving average is $103.44 and its two-hundred day simple moving average is $103.19.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the prior year, the company posted ($1.18) EPS. As a group, equities analysts forecast that Nuvalent will post -5.74 earnings per share for the current fiscal year.

Insider Activity at Nuvalent

In other news, insider Deborah Ann Miller sold 5,500 shares of Nuvalent stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total transaction of $593,120.00. Following the completion of the sale, the insider owned 59,634 shares of the company’s stock, valued at approximately $6,430,930.56. The trade was a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Alexandra Balcom sold 11,430 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $98.69, for a total transaction of $1,128,026.70. Following the completion of the sale, the chief financial officer directly owned 85,533 shares of the company’s stock, valued at $8,441,251.77. The trade was a 11.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 126,953 shares of company stock worth $12,612,264. Insiders own 5.02% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after acquiring an additional 195 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Nuvalent during the third quarter valued at approximately $38,000. NBC Securities Inc. purchased a new stake in Nuvalent during the fourth quarter valued at approximately $125,000. Finally, KBC Group NV lifted its position in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after acquiring an additional 297 shares during the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s all-cash acquisition offer values Nuvalent at roughly $10.6 billion and implies a meaningful premium to recent trading levels, giving shareholders a clear exit price. Reuters article on GSK deal
• Positive Sentiment: Analysts and market commentary suggest the deal makes strategic sense for GSK because Nuvalent brings a late-stage lung cancer pipeline, reinforcing investor confidence that the transaction is real and financially significant. WSJ article on GSK deal
• Neutral Sentiment: Several law firms have launched investigations into whether the sale process and $124.00 price are fair to shareholders, which could create some headline noise but does not change the announced deal terms yet. Business Wire article on investigation
• Neutral Sentiment: Wells Fargo and other brokers trimmed ratings after the takeover announcement, but their updated price targets remain near the deal value, so these moves are unlikely to outweigh the acquisition news. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly pressure sentiment by reinforcing that insiders have been reducing exposure ahead of the transaction. SEC insider filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.